Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rule 4.10.3. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s Principles and Recommendations, detailing its governance framework, board responsibilities, and performance evaluations. This document highlights Imugene’s commitment to maintaining high standards of ethics, integrity, and statutory compliance, which are crucial for its strategic direction and operational management. The statement also addresses areas where recommendations were not fully followed, ensuring transparency and accountability to stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of innovative cancer immunotherapies. The company is dedicated to advancing its pipeline of products aimed at enhancing the body’s immune response to fight cancer, positioning itself as a key player in the oncology market.
Average Trading Volume: 1,646,640
Technical Sentiment Signal: Sell
Current Market Cap: A$82.22M
See more data about IMU stock on TipRanks’ Stock Analysis page.